Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
CR Dunlop, Y Wallez, TI Johnson… - British journal of …, 2020 - nature.com
CR Dunlop, Y Wallez, TI Johnson, S Bernaldo de Quirós Fernández, ST Durant…
British journal of cancer, 2020•nature.comBackground Personalised medicine strategies may improve outcomes in pancreatic ductal
adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having
developed a clinical trial to assess the ATR inhibitor, AZD6738, in combination with
gemcitabine (ATRi/gem), we investigated ATM loss as a predictive biomarker of response to
ATRi/gem in PDAC. Methods Through kinase inhibition, siRNA depletion and CRISPR
knockout of ATM, we assessed how ATM targeting affected the sensitivity of PDAC cells to …
adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having
developed a clinical trial to assess the ATR inhibitor, AZD6738, in combination with
gemcitabine (ATRi/gem), we investigated ATM loss as a predictive biomarker of response to
ATRi/gem in PDAC. Methods Through kinase inhibition, siRNA depletion and CRISPR
knockout of ATM, we assessed how ATM targeting affected the sensitivity of PDAC cells to …
Background
Personalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR inhibitor, AZD6738, in combination with gemcitabine (ATRi/gem), we investigated ATM loss as a predictive biomarker of response to ATRi/gem in PDAC.
Methods
Through kinase inhibition, siRNA depletion and CRISPR knockout of ATM, we assessed how ATM targeting affected the sensitivity of PDAC cells to ATRi/gem. Using flow cytometry, immunofluorescence and immunoblotting, we investigated how ATRi/gem synergise in ATM-proficient and ATM-deficient cells, before assessing the impact of ATM loss on ATRi/gem sensitivity in vivo.
Results
Complete loss of ATM function (through pharmacological inhibition or CRISPR knockout), but not siRNA depletion, sensitised to ATRi/gem. In ATM-deficient cells, ATRi/gem-induced replication catastrophe was augmented, while phospho-Chk2-T68 and phospho-KAP1-S824 persisted via DNA-PK activity. ATRi/gem caused growth delay in ATM-WT xenografts in NSG mice and induced regression in ATM-KO xenografts.
Conclusions
ATM loss augments replication catastrophe-mediated cell death induced by ATRi/gem and may predict clinical responsiveness to this combination. ATM status should be carefully assessed in tumours from patients with PDAC, since distinction between ATM-low and ATM-null could be critical in maximising the success of clinical trials using ATM expression as a predictive biomarker.
nature.com
